ArticleMolecular and cellular pharmacology2009
A Potential Preclinical Migraine Model: CGRP-Sensitized Mice.
Article in Molecular and cellular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.The journal of headache and pain · 2024Pooled it
- PACAP versus CGRP in migraine: From mouse models to clinical translation.Cephalalgia : an international journal of headache · 2025Review
- Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study.Therapeutic advances in neurological disorders · 2025Article
- Molecular nociceptive mechanisms in migraine: The migraine cascade.European journal of neurology · 2024Review
- New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.Frontiers in neurology · 2024Review
- Human RAMP1 overexpressing mice are resistant to migraine therapies for motion sensitivity.PloS one · 2024Article
- Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides.International journal of molecular sciences · 2023Review
- Estradiol Treatment Enhances Behavioral and Molecular Changes Induced by Repetitive Trigeminal Activation in a Rat Model of Migraine.Biomedicines · 2022Article
- PACAP Induces Light Aversion in Mice by an Inheritable Mechanism Independent of CGRP.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Effects of Calcitonin-Gene-Related-Peptide on Auditory Nerve Activity.Frontiers in cell and developmental biology · 2021Article
- Article
- From transformation to chronification of migraine: pathophysiological and clinical aspects.The journal of headache and pain · 2020Review
- CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.International journal of molecular sciences · 2019Article
- Animal models of migraine and experimental techniques used to examine trigeminal sensory processing.The journal of headache and pain · 2019Review
- CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.Current pain and headache reports · 2019Review
- CGRP in Animal Models of Migraine.Handbook of experimental pharmacology · 2019Review
- Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1.British journal of pharmacology · 2017Article
- Pathophysiology of Migraine: A Disorder of Sensory Processing.Physiological reviews · 2017Review
- Trigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury.Journal of neurotrauma · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The neuropeptide calcitonin gene-related peptide (CGRP) plays a key role in migraine. However, a major challenge for studying CGRP actions is the lack of animal models for migraine. Clinical studies suggested that migraineurs are more sensitive to CGRP than people who do not suffer from migraine. We therefore generated a transgenic mouse that is sensitized to CGRP (nestin/hRAMP1 mice). The mice have elevated expression of a subunit of the CGRP receptor, human receptor activity-modifying protein 1 (hRAMP1). Nestin/hRAMP1 mice have two symptoms of migraine: photophobia and mechanical allodynia. The light aversion was greatly enhanced by intracerebroventricular administration of CGRP. CGRP had little effect on motility in the light zone, but once in the dark, the mice moved less than controls. The CGRP-induced light aversion was attenuated by co-administration of the CGRP receptor antagonist olcegepant. These findings suggest that CGRP acts as a neuromodulator to increase sensory responses and that regulation of a single gene, hRAMP1, could potentially contribute to migraine susceptibility.
Identifiers
20336186PMC2844716W1558116296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.